These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 35007141)
1. Optimized Loading Dose Strategies for Bedaquiline When Restarting Interrupted Drug-Resistant Tuberculosis Treatment. Koele SE; van Beek SW; Maartens G; Brust JCM; Svensson EM Antimicrob Agents Chemother; 2022 Mar; 66(3):e0174921. PubMed ID: 35007141 [TBL] [Abstract][Full Text] [Related]
2. A modeling-based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics study. Keutzer L; Akhondipour Salehabad Y; Davies Forsman L; Simonsson USH CPT Pharmacometrics Syst Pharmacol; 2022 May; 11(5):628-639. PubMed ID: 35102712 [TBL] [Abstract][Full Text] [Related]
3. Addressing bedaquiline treatment interruptions in the treatment of drug-resistant TB. Kambili C; Rossenu S; Hoetelmans RMW; Birmingham E; Bakare N Int J Tuberc Lung Dis; 2022 Jul; 26(7):671-677. PubMed ID: 35768912 [TBL] [Abstract][Full Text] [Related]
4. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis. Worley MV; Estrada SJ Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970 [TBL] [Abstract][Full Text] [Related]
5. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Chahine EB; Karaoui LR; Mansour H Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600 [TBL] [Abstract][Full Text] [Related]
6. A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis. Cohen K; Maartens G Expert Opin Drug Saf; 2019 Oct; 18(10):875-882. PubMed ID: 31339384 [No Abstract] [Full Text] [Related]
7. Pharmacokinetics and Safety of Bedaquiline in Human Immunodeficiency Virus (HIV)-Positive and Negative Older Children and Adolescents With Rifampicin-Resistant Tuberculosis. Hughes JA; Solans BP; Draper HR; Schaaf HS; Winckler JL; van der Laan L; Radtke KK; Fourie B; Wiesner L; Hesseling AC; Savic RM; Garcia-Prats AJ Clin Infect Dis; 2022 Nov; 75(10):1772-1780. PubMed ID: 35377434 [TBL] [Abstract][Full Text] [Related]
8. Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety. Gao JT; Du J; Wu GH; Pei Y; Gao MQ; Martinez L; Fan L; Chen W; Xie L; Chen Y; Wang H; Jin L; Li GB; Zong PL; Xiong Y; Wu QH; Li MW; Yan XF; Miao YF; Cai QS; Li XJ; Bai DP; Geng SJ; Yang GL; Tang PJ; Zeng Y; Chen XH; Li TX; Cai C; Zhou Y; Zhuo M; Wang JY; Guan WL; Xu L; Shi JC; Shu W; Cheng LL; Teng F; Ning YJ; Xie SH; Sun YX; Zhang LJ; Liu YH Infect Dis Poverty; 2021 Mar; 10(1):32. PubMed ID: 33736710 [TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetic Analysis of Bedaquiline-Clarithromycin for Dose Selection Against Pulmonary Nontuberculous Mycobacteria Based on a Phase 1, Randomized, Pharmacokinetic Study. Kurosawa K; Rossenu S; Biewenga J; Ouwerkerk-Mahadevan S; Willems W; Ernault E; Kambili C J Clin Pharmacol; 2021 Oct; 61(10):1344-1355. PubMed ID: 33991350 [TBL] [Abstract][Full Text] [Related]
10. Bedaquiline: a novel antitubercular drug for multidrug-resistant tuberculosis. Nagabushan H; Roopadevi HS J Postgrad Med; 2014; 60(3):300-2. PubMed ID: 25121373 [TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin. Svensson EM; Dosne AG; Karlsson MO CPT Pharmacometrics Syst Pharmacol; 2016 Dec; 5(12):682-691. PubMed ID: 27863179 [TBL] [Abstract][Full Text] [Related]
12. Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis. Brill MJ; Svensson EM; Pandie M; Maartens G; Karlsson MO Int J Antimicrob Agents; 2017 Feb; 49(2):212-217. PubMed ID: 28038962 [TBL] [Abstract][Full Text] [Related]
13. Bedaquiline: a new drug approved for treatment of multidrug-resistant tuberculosis. Deoghare S Indian J Pharmacol; 2013; 45(5):536-7. PubMed ID: 24130398 [No Abstract] [Full Text] [Related]
14. Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB). Upton CM; Steele CI; Maartens G; Diacon AH; Wiesner L; Dooley KE J Antimicrob Chemother; 2022 May; 77(6):1720-1724. PubMed ID: 35257182 [TBL] [Abstract][Full Text] [Related]
15. Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients. Barvaliya SV; Desai MK; Panchal JR; Solanki RN Indian J Tuberc; 2020 Apr; 67(2):222-230. PubMed ID: 32553316 [TBL] [Abstract][Full Text] [Related]
16. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. Svensson EM; Murray S; Karlsson MO; Dooley KE J Antimicrob Chemother; 2015 Apr; 70(4):1106-14. PubMed ID: 25535219 [TBL] [Abstract][Full Text] [Related]
17. Use of bedaquiline in spinal osteomyelitis and soft tissue abscess caused by multidrug-resistant Mycobacterium tuberculosis: A case report. De Vito A; Fiore V; Urru V; Bozzi E; Geremia N; Princic E; Canu D; Molicotti P; Are R; Babudieri S; Madeddu G Braz J Infect Dis; 2022; 26(5):102701. PubMed ID: 36096158 [TBL] [Abstract][Full Text] [Related]
18. Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis. Perrineau S; Lachâtre M; Lê MP; Rioux C; Loubet P; Fréchet-Jachym M; Gonzales MC; Grall N; Bouvet E; Veziris N; Yazdanpanah Y; Peytavin G Int J Tuberc Lung Dis; 2019 Jan; 23(1):99-104. PubMed ID: 30674381 [TBL] [Abstract][Full Text] [Related]
19. Bedaquiline and delamanid in tuberculosis. Esposito S; Bianchini S; Blasi F Expert Opin Pharmacother; 2015; 16(15):2319-30. PubMed ID: 26293803 [TBL] [Abstract][Full Text] [Related]
20. Exposure-safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug-resistant tuberculosis. Tanneau L; Svensson EM; Rossenu S; Karlsson MO CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1538-1549. PubMed ID: 34626526 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]